Logo image of MOLN

MOLECULAR PARTNERS AG -ADR (MOLN) Stock Price, Quote, News and Overview

NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD

4.681  -0.23 (-4.75%)

MOLN Quote, Performance and Key Statistics

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (2/21/2025, 8:00:01 PM)

4.681

-0.23 (-4.75%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12.7
52 Week Low3.32
Market Cap172.56M
Shares36.86M
Float29.12M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-06 2025-03-06/amc
IPO10-22 2014-10-22


MOLN short term performance overview.The bars show the price performance of MOLN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

MOLN long term performance overview.The bars show the price performance of MOLN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of MOLN is 4.681 USD. In the past month the price decreased by -13.23%. In the past year, price increased by 16.73%.

MOLECULAR PARTNERS AG -ADR / MOLN Daily stock chart

MOLN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About MOLN

Company Profile

MOLN logo image Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 162 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Company Info

MOLECULAR PARTNERS AG -ADR

Wagistrasse 14

Schlieren ZUERICH CH

CEO: Patrick Amstutz

Employees: 162

Company Website: https://www.molecularpartners.com/

Investor Relations: https://investors.molecularpartners.com/

Phone: 41447557700

MOLECULAR PARTNERS AG -ADR / MOLN FAQ

What is the stock price of MOLECULAR PARTNERS AG -ADR today?

The current stock price of MOLN is 4.681 USD. The price decreased by -4.75% in the last trading session.


What is the ticker symbol for MOLECULAR PARTNERS AG -ADR stock?

The exchange symbol of MOLECULAR PARTNERS AG -ADR is MOLN and it is listed on the Nasdaq exchange.


On which exchange is MOLN stock listed?

MOLN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MOLECULAR PARTNERS AG -ADR stock?

9 analysts have analysed MOLN and the average price target is 12.04 USD. This implies a price increase of 157.12% is expected in the next year compared to the current price of 4.681. Check the MOLECULAR PARTNERS AG -ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MOLECULAR PARTNERS AG -ADR worth?

MOLECULAR PARTNERS AG -ADR (MOLN) has a market capitalization of 172.56M USD. This makes MOLN a Micro Cap stock.


How many employees does MOLECULAR PARTNERS AG -ADR have?

MOLECULAR PARTNERS AG -ADR (MOLN) currently has 162 employees.


What are the support and resistance levels for MOLECULAR PARTNERS AG -ADR (MOLN) stock?

MOLECULAR PARTNERS AG -ADR (MOLN) has a support level at 4.67 and a resistance level at 4.88. Check the full technical report for a detailed analysis of MOLN support and resistance levels.


Is MOLECULAR PARTNERS AG -ADR (MOLN) expected to grow?

The Revenue of MOLECULAR PARTNERS AG -ADR (MOLN) is expected to decline by -25% in the next year. Check the estimates tab for more information on the MOLN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MOLECULAR PARTNERS AG -ADR (MOLN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MOLECULAR PARTNERS AG -ADR (MOLN) stock pay dividends?

MOLN does not pay a dividend.


When does MOLECULAR PARTNERS AG -ADR (MOLN) report earnings?

MOLECULAR PARTNERS AG -ADR (MOLN) will report earnings on 2025-03-06, after the market close.


What is the Price/Earnings (PE) ratio of MOLECULAR PARTNERS AG -ADR (MOLN)?

MOLECULAR PARTNERS AG -ADR (MOLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.07).


What is the Short Interest ratio of MOLECULAR PARTNERS AG -ADR (MOLN) stock?

The outstanding short interest for MOLECULAR PARTNERS AG -ADR (MOLN) is 0.16% of its float. Check the ownership tab for more information on the MOLN short interest.


MOLN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to MOLN. When comparing the yearly performance of all stocks, MOLN turns out to be only a medium performer in the overall market: it outperformed 55.47% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MOLN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MOLN. The financial health of MOLN is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MOLN Financial Highlights

Over the last trailing twelve months MOLN reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 23.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -40.48%
ROE -44.4%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%51.11%
Sales Q2Q%-57.93%
EPS 1Y (TTM)23.6%
Revenue 1Y (TTM)-25.37%

MOLN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to MOLN. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 17.79% and a revenue growth -25% for MOLN


Ownership
Inst Owners45.23%
Ins Owners4.04%
Short Float %0.16%
Short Ratio3.54
Analysts
Analysts82.22
Price Target12.04 (157.21%)
EPS Next Y17.79%
Revenue Next Year-25%